Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH-exendin-4 for the diagnosis of recurrence or dissemination of medullary thyroid cancer: A preliminary report

International Journal of Endocrinology

Volumn 2013, Issue , 2013, Pages

  Pach, D ^a   Sowa Staszczak, A ^a   Jabrocka Hybel, A ^a   Stefanska A ^a   Tomaszuk, M ^a   Mikolajczak R ^b   Janota, B ^b   Trofimiuk Muldner M ^a   Przybylik Mazurek, E ^a   Hubalewska Dydejczyk, A ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b NATIONAL CENTRE FOR NUCLEAR RESEARCH   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

[LYSINE 40 (AMINOHEXANOIC ACID HYNIC EDDA)AMIDE]EXENDIN 4 TC 99M; DOTA TATE Y 90; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; IODINE 131; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; ECHOGRAPHY; FEMALE; HUMAN; IMAGE QUALITY; INTERMETHOD COMPARISON; LIVER DISEASE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; PRIORITY JOURNAL; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; THYROID MEDULLARY CARCINOMA; THYROID SCINTISCANNING; THYROIDECTOMY;

EID: 84877310371     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/384508     Document Type: Article

References (35)

1. Sippel R. S., Kunnimalaiyaan M., Chen H., Current management of medullary thyroid cancer. Oncologist 2008 13 5 539 547 2-s2.0-45749139320 10.1634/theoncologist.2007-0239 (Pubitemid 351872871)
2. Ball D. W., Medullary thyroid cancer: monitoring and therapy. Endocrinology and Metabolism Clinics of North America 2007 36 3 823 837 (Pubitemid 47126253)
3. Ball D. W., Medullary thyroid cancer: therapeutic targets and molecular markers. Current Opinion in Oncology 2007 19 1 18 23 2-s2.0-33845356681 10.1097/CCO.0b013e32801173ea (Pubitemid 44885595)
4. Machens A., Ukkat J., Hauptmann S., Dralle H., Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Archives of Surgery 2007 142 3 289 293 2-s2.0-33947371271 10.1001/archsurg.142.3.289 (Pubitemid 46457057)
5. Moley J. F., Lairmore T. C., Phay J. E., Hereditary endocrinopathies. Current Problems in Surgery 1999 36 9 653 762 2-s2.0-0033191023
6. Kebebew E., Kikuchi S., Duh Q.-Y., Clark O. H., Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Archives of Surgery 2000 135 8 895 901 2-s2.0-0033868467 (Pubitemid 30625965)
7. Pacini F., Castagna M. G., Cipri C., Schlumberger M., Medullary thyroid carcinoma. Clinical Oncology 2010 22 6 475 485 2-s2.0-77954757206 10.1016/j.clon.2010.05.002
8. American Thyroid Association Guidelines Task Force, Kloos R. T., Eng C., Evans D. B., Francis G. L., Gagel R. F., Gharib H., Moley J. F., Pacini F., Ringel M. D., Schlumberger M., Wells S. A., Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009 19 6 565 612 2-s2.0-67749130797
9. Elisei R., Cosci B., Romei C., Bottici V., Renzini G., Molinaro E., Agate L., Vivaldi A., Faviana P., Basolo F., Miccoli P., Berti P., Pacini F., Pinchera A., Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. Journal of Clinical Endocrinology and Metabolism 2008 93 3 682 687 2-s2.0-40849094269 10.1210/jc.2007-1714 (Pubitemid 351398539)
10. Scollo C., Baudin E., Travagli J. P., Caillou B., Bellon N., Leboulleux S., Schlumberger M., Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2003 88 5 2070 2075 2-s2.0-0038369070 10.1210/jc.2002-021713 (Pubitemid 36549878)
11. Machens A., Schneyer U., Holzhausen H. J., Dralle H., Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. Journal of Clinical Endocrinology and Metabolism 2005 90 4 2029 2034 2-s2.0-17844400055 10.1210/jc.2004-1836 (Pubitemid 40586235)
12. Giraudet A. L., Al Ghulzan A., Aupérin A., Leboulleux S., Chehboun A., Troalen F., Dromain C., Lumbroso J., Baudin E., Schlumberger M., Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. European Journal of Endocrinology 2008 158 2 239 246 2-s2.0-38949129191 10.1530/EJE-07-0667 (Pubitemid 351298542)
13. Reubi J. C., Waser B., Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. European Journal of Nuclear Medicine and Molecular Imaging 2003 30 5 781 793 2-s2.0-0037907532 (Pubitemid 36612963)
14. Wild D., Mäcke H., Christ E., Gloor B., Reubi J. C., Glucagon-like peptide 1-receptor scans to localize occult insulinomas. The New England Journal of Medicine 2008 359 7 766 768 2-s2.0-49449085799 10.1056/NEJMc0802045
15. Christ E., Wild D., Forrer F., Brändle M., Sahli R., Clerici T., Gloor B., Martius F., Maecke H., Reubi J. C., Glucagon-like peptide-1 receptor imaging for localization of insulinomas. Journal of Clinical Endocrinology and Metabolism 2009 94 11 4398 4405 2-s2.0-70449111654 10.1210/jc.2009-1082
16. Wild D., Wicki A., Mansi R., Béhé M., Keil B., Bernhardt P., Christofori G., Ell P. J., Mäcke H. R., Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. Journal of Nuclear Medicine 2010 51 7 1059 1067 2-s2.0-77954986457 10.2967/jnumed.110.074914
17. Tai D., Poon D., Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers. Journal of Oncology 2010 2010 7 2-s2.0-77957947626 10.1155/2010/398564 398564
18. Rufini V., Salvatori M., Garganese M. C., Di Giuda D., Lodovica Maussier M., Troncone L., Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays 2000 25 2 273 282 2-s2.0-0034173478
19. Pinchot S. N., Kunnimalaiyaan M., Sippel R. S., Chen H., Medullary thyroid carcinoma: targeted therapies and future directions. Journal of Oncology 2009 2009 7 2-s2.0-75449097942 10.1155/2009/183031 183031
20. Santarpia L., Ye L., Gagel R. F., Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. Journal of Internal Medicine 2009 266 1 99 113 2-s2.0-66849128386 10.1111/j.1365-2796.2009. 02112.x
21. 99mTc-DMSA (V)] in detection of metastases of medullary thyroid carcinoma. Iranian Journal of Nuclear Medicine 2006 14 26 15 24 2-s2.0-33846796073
22. Haugen B. R., Lin E. C., Isotope imaging for metastatic thyroid cancer. Endocrinology Metabolism Clinics of North America 2001 30 469 492 (Pubitemid 32606683)
23. 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. European Journal of Nuclear Medicine 1996 23 10 1367 1371 2-s2.0-0029665302 10.1007/BF01367593 (Pubitemid 26340590)
24. Rufini V., Salvatori M., Garganese M. C., Di Giuda D., Lodovica Maussier M., Troncone L., Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays 2000 25 2 273 282 2-s2.0-0034173478
25. Guilloteau D., Baulieu J. L., Besnard J. C., Medullary-thyroid-carcinoma imaging in an animal model: use of radiolabeled anticalcitonin F(ab')2 and meta-iodobenzylguanidine. European Journal of Nuclear Medicine 1985 11 6-7 198 200 2-s2.0-0022343365 (Pubitemid 16233600)
26. Krenning E. P., Lamberts S. W. J., Reubi J. C., Somatostatin receptor imaging in medullary thyroid carcinoma. Thyroid 1991 1 supplement 1 564
27. Kaltsas G., Korbonits M., Heintz E., Mukherjee J. J., Jenkins P. J., Chew S. L., Reznek R., Monson J. P., Besser G. M., Foley R., Britton K. E., Grossman A. B., Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. Journal of Clinical Endocrinology and Metabolism 2001 86 2 895 902 2-s2.0-17744373472 10.1210/jc.86.2.895 (Pubitemid 32207512)
28. 99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery. Clinical Nuclear Medicine 2001 26 8 683 688 2-s2.0-0034919634 10.1097/00003072-200108000-00004 (Pubitemid 32664266)
29. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. Journal of Nuclear Medicine 2002 43 1 66 71 2-s2.0-0036007410 (Pubitemid 34101190)
30. 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature. Nuclear Medicine Communications 2004 25 5 439 443 2-s2.0-16544377183 10.1097/00006231-200405000-00003 (Pubitemid 38591103)
31. 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. Journal of Nuclear Medicine 2007 48 4 501 507 2-s2.0-34248594179 10.2967/jnumed.106.036681 (Pubitemid 47571403)
32. 18F-FDG PET-CT. European Radiology 2009 19 6 1425 1434
33. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. European Journal of Nuclear Medicine 2001 28 1 64 71 2-s2.0-0034746433 10.1007/s002590000404 (Pubitemid 32120808)
34. Körner M., Stöckli M., Waser B., GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. Journal of Nuclear Medicine 2007 48 736 743 (Pubitemid 47604973)
35. Gier B., Butler P. C., Lai C. K., Glucagon like peptide-1 receptor expression in the human thyroid gland. The Journal of Clinical Endocrinology & Metabolism 2012 97 121 131